Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096381 · ClinicalTrials.gov registry record
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- 8
- Enrollment target
NCT01096381 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 8 participants.
The verdict
NCT01096381 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure. PURPOSE: This phase I trial is studying potential biomarkers for bevacizumab-induced high blood pressure in patients with malignant solid tumors, including breast cancer, colorectal cancer, non-small cell lung cancer, head and neck cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01096381
The ClinicalTrials.gov registry entry for NCT01096381 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01096381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01096381 about?
NCT01096381 is a clinical study titled "Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor". RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure. PURPOSE: This phase I trial is studying potential biomarkers for bevac...
What is the current status of trial NCT01096381?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2010-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01096381?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT01096381?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.